KV Pharmaceutical Sets Record Date for Stockholder Action by Writt...(es the following cautionary statements i...),Health

Date:9/9/2009

es the following cautionary statements identifying important economic, political and technological factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) the ability to continue as a going concern; (2) changes in the current and future business environment, including interest rates and capital and consumer spending; (3) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (4) the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals; (5) acceptance and demand for new pharmaceutical products; (6) the introduction and impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (7) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (8) reliance on key strategic alliances; (9) the availability of raw materials and/or products manufactured for the Company under contract manufacturing arrangements with third parties; (10) the regulatory environment, including regulatory agency and judicial actions and changes in applicable law or regulations; (11) fluctuations in revenues; (12) the difficulty of predicting international regulatory approvals, including timing; (13) the difficulty of predicting the pattern of inventory movements by the Company's customers; (14) the impact of competitive response to the Company's sales, marketing and strategic efforts, including the introduction or potential introduction of generic or competing products against products sold by the Company and its subsidiaries; (15) risks that the Company may not ultimately prevail in litigation, including challenges to the Company's intellectual property rights by a
'/>"/>

SOURCE KV Pharmaceutical Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
2. Isis Pharmaceuticals to Present at Morgan Stanleys Global Healthcare Unplugged Conference
3. FDA pharmaceutical import alert
4. KV Pharmaceutical Appoints Interim Chief Financial Officer
5. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
6. Jazz Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
9. Steven Holtzman Joins Satori Pharmaceuticals Board of Directors
10. Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
11. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2010